[A23-76] Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2024
Project no.:
A23-76
Commission:
Commission awarded on 01.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adult patients with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-76
| Project no. | Title | Status |
|---|---|---|
| A23-132 | Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76 | Commission completed |
Federal Joint Committee (G-BA)
2024-02-01 A G-BA decision was published.